Should I buy or sell Fresenius Medical Care AG & Co. KGaA stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fresenius Medical Care AG & Co. KGaA in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FMS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FMS, but not buy additional shares or sell existing shares. View FMS analyst ratings or view top-rated stocks .

What is Fresenius Medical Care AG & Co. KGaA's stock price target for 2024?

9 brokerages have issued 1-year price targets for Fresenius Medical Care AG & Co. KGaA's shares. Their FMS share price targets range from $11.70 to $24.00. On average, they predict the company's share price to reach $17.85 in the next twelve months. This suggests that the stock has a possible downside of 12.7%. View analysts price targets for FMS or view top-rated stocks among Wall Street analysts .

How have FMS shares performed in 2023?

Fresenius Medical Care AG & Co. KGaA's stock was trading at $16.34 on January 1st, 2023. Since then, FMS stock has increased by 25.1% and is now trading at $20.44. View the best growth stocks for 2023 here .

Are investors shorting Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 1,250,000 shares, a drop of 41.6% from the October 31st total of 2,140,000 shares. Based on an average trading volume of 575,200 shares, the short-interest ratio is currently 2.2 days. View Fresenius Medical Care AG & Co. KGaA's Short Interest .

When is Fresenius Medical Care AG & Co. KGaA's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our FMS earnings forecast .

How were Fresenius Medical Care AG & Co. KGaA's earnings last quarter?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) announced its quarterly earnings data on Wednesday, November, 1st. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by $0.06. The business earned $5.37 billion during the quarter, compared to analysts' expectations of $5.42 billion. Fresenius Medical Care AG & Co. KGaA had a trailing twelve-month return on equity of 4.85% and a net margin of 2.30%. During the same quarter in the prior year, the firm posted $0.40 EPS.

How often does Fresenius Medical Care AG & Co. KGaA pay dividends? What is the dividend yield for Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA announced an annual dividend on Wednesday, May 3rd. Investors of record on Thursday, May 18th will be paid a dividend of $0.7086 per share on Thursday, June 1st. This represents a dividend yield of 2.1%. The ex-dividend date is Wednesday, May 17th. Read our dividend analysis for FMS .

Is Fresenius Medical Care AG & Co. KGaA a good dividend stock?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) pays an annual dividend of $0.42 per share and currently has a dividend yield of 2.06%. The dividend payout ratio is 51.22%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, FMS will have a dividend payout ratio of 26.25% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for FMS .

What ETFs hold Fresenius Medical Care AG & Co. KGaA's stock?

ETFs with the largest weight of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) stock in their portfolio include Invesco International Dividend Achievers ETF (PID) . Cultivar ETF (CVAR) .

What other stocks do shareholders of Fresenius Medical Care AG & Co. KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fresenius Medical Care AG & Co. KGaA investors own include Energy Transfer (ET) , Petra Diamonds (PDL) , AT&T (T) , Pfizer (PFE) , AbbVie (ABBV) , Gilead Sciences (GILD) , Merck & Co., Inc. (MRK) , Abbott Laboratories (ABT) , Chevron (CVX) and Ford Motor (F) .

Who are Fresenius Medical Care AG & Co. KGaA's major shareholders?

Fresenius Medical Care AG & Co. KGaA's stock is owned by many different institutional and retail investors. Top institutional shareholders include Pzena Investment Management LLC (2.78%), Morgan Stanley (0.18%), Invesco Ltd. (0.14%), Envestnet Asset Management Inc. (0.04%), Northern Trust Corp (0.04%) and O Shaughnessy Asset Management LLC (0.02%).

How do I buy shares of Fresenius Medical Care AG & Co. KGaA?

Shares of FMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Fresenius Medical Care AG & Co. KGaA have any subsidiaries?

The following companies are subsidiares of Fresenius Medical Care AG & Co. KGaA: NxStage Medical. Read More

Fresenius Medical Care AG & Co. KGaA Stock Price, News & Analysis (NYSE:FMS)

$20.42

+0.01 (+0.05%)

(As of 03:46 PM ET)

Compare

Today's Range: $20.42
▼
$20.59
50-Day Range: $16.40
▼
$23.09
52-Week Range: $15.28
▼
$27.72

Volume: 223,276 shs
Average Volume: 653,686 shs
Market Capitalization: $11.98 billion

P/E Ratio: 24.90
Dividend Yield: 2.06%
Price Target: $17.85

Fresenius Medical Care AG & Co. KGaA MarketRank™ Stock Analysis

Analyst Rating: Hold
2.11 Rating Score
Upside/Downside: 12.7% Downside
$17.85 Price Target
Short Interest: Healthy
0.21% of Shares Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: 1.45
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 26.98%
From $1.26 to $1.60 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

248th out of 949 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

2nd out of 7 stocks

1.1

Analyst's Opinion

Consensus Rating
Fresenius Medical Care AG & Co. KGaA has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 2 buy ratings, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $17.85, Fresenius Medical Care AG & Co. KGaA has a forecasted downside of 12.7% from its current price of $20.44.
Amount of Analyst Coverage
Fresenius Medical Care AG & Co. KGaA has only been the subject of 4 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.21% of the outstanding shares of Fresenius Medical Care AG & Co. KGaA have been sold short.
Short Interest Ratio / Days to Cover
Fresenius Medical Care AG & Co. KGaA has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Fresenius Medical Care AG & Co. KGaA has recently decreased by 41.59%, indicating that investor sentiment is improving significantly.

2.5

Dividend Strength

Dividend Yield
Fresenius Medical Care AG & Co. KGaA pays a meaningful dividend of 2.06%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Fresenius Medical Care AG & Co. KGaA does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Fresenius Medical Care AG & Co. KGaA is 51.22%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Fresenius Medical Care AG & Co. KGaA will have a dividend payout ratio of 26.25% next year. This indicates that Fresenius Medical Care AG & Co. KGaA will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FMS.

3.0

News and Social Media Coverage

News Sentiment
Fresenius Medical Care AG & Co. KGaA has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Fresenius Medical Care AG & Co. KGaA this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 3 people have added Fresenius Medical Care AG & Co. KGaA to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fresenius Medical Care AG & Co. KGaA insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 5.81% of the stock of Fresenius Medical Care AG & Co. KGaA is held by institutions.

3.8

Earnings and Valuation

Earnings Growth
Earnings for Fresenius Medical Care AG & Co. KGaA are expected to grow by 26.98% in the coming year, from $1.26 to $1.60 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fresenius Medical Care AG & Co. KGaA is 24.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.36.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fresenius Medical Care AG & Co. KGaA is 24.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.85.
Price to Book Value per Share Ratio
Fresenius Medical Care AG & Co. KGaA has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fresenius Medical Care AG & Co. KGaA Stock (NYSE:FMS)

Fresenius Medical Care AG & Co. KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

FMS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FMS Stock News Headlines

November 25, 2023 | americanbankingnews.com

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Upgraded by HSBC to Hold

November 24, 2023 | finance.yahoo.com

Be Wary Of Fresenius Medical Care KGaA (ETR:FME) And Its Returns On Capital

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 23, 2023 | finance.yahoo.com

Fresenius Medical (FMS) Ups '23 Outlook After Legal Settlement

November 21, 2023 | finance.yahoo.com

Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million - 2023 earnings outlook raised

November 19, 2023 | americanbankingnews.com

Societe Generale Upgrades Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) to Buy

November 7, 2023 | finance.yahoo.com

At €32.00, Is Fresenius Medical Care AG & Co. KGaA (ETR:FME) Worth Looking At Closely?

November 3, 2023 | finance.yahoo.com

Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 3, 2023 | finance.yahoo.com

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Q3 2023 Earnings Call Transcript

November 2, 2023 | finance.yahoo.com

Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care Earnings: Underlying Growth and Margin Improvement Boost 2023 Outlook

October 24, 2023 | finance.yahoo.com

Zacks Investment Ideas feature highlights: Fresenius Medical Care, Vericel and ImmunoGen

October 24, 2023 | finance.yahoo.com

NeoGenomics and SolarEdge Technologies have been highlighted as Zacks Bull and Bear of the Day

October 22, 2023 | finance.yahoo.com

Fresenius Medical Care AG & Co. KGaA (ETR:FME) is a favorite amongst institutional investors who own 42%

October 20, 2023 | finance.yahoo.com

Are Investors Undervaluing Fresenius Medical Care AG & Co. (FMS) Right Now?

October 12, 2023 | seekingalpha.com

Fresenius sees GLP-1 drugs having neutral impact on its business: report